Read by QxMD icon Read

Clinical Genitourinary Cancer

Solomon L Woldu, Justin T Matulay, Timothy N Clinton, Nirmish Singla, Yuval Freifeld, Oner Sanli, Laura-Maria Krabbe, Ryan C Hutchinson, Yair Lotan, Hans Hammers, Raquibul Hannan, James Brugarolas, Aditya Bagrodia, Vitaly Margulis
BACKGROUND: The optimal timing of targeted therapy (TT) initiation for metastatic renal-cell carcinoma (mRCC) is not clear. We used a nationwide cancer registry to determine clinical and social factors associated with delayed TT and to evaluate the association of a delayed approach with overall survival (OS). PATIENTS AND METHODS: We performed a retrospective observational study utilizing the National Cancer Data Base from 2006 to 2012 for patients diagnosed with mRCC (clear-cell histology) treated with cytoreductive nephrectomy and TT...
August 25, 2018: Clinical Genitourinary Cancer
Nima Almassi, Tianming Gao, Byron Lee, Robert J Stein, Georges-Pascal Haber, Moshe C Ornstein, Brian I Rini, Timothy D Gilligan, Jorge A Garcia, Andrew J Stephenson, Petros Grivas
BACKGROUND: Neoadjuvant chemotherapy (NAC) has been increasingly adopted in the management of high-grade upper tract urothelial carcinoma (UTUC), largely extrapolating from level I evidence in urothelial carcinoma of the bladder. Studies examining pathologic outcomes in patients with UTUC receiving NAC are mostly limited to retrospective, single-center studies with limited sample size, with results of a phase II trial recently presented. Hypothesizing that NAC is associated with improved pathologic response (PR), we compared pathologic outcomes in patients with high-grade UTUC who did and did not receive NAC before extirpative surgery...
August 22, 2018: Clinical Genitourinary Cancer
Pedro C Barata, Prateek Mendiratta, Rupesh Kotecha, Dharmesh Gopalakrishnan, Aditya Juloori, Samuel T Chao, Vadim Koshkin, Moshe Ornstein, Timothy D Gilligan, Laura S Wood, Brian I Rini, Lilyana Angelov, Jorge A Garcia
BACKGROUND: We assessed the clinical outcomes of patients with oligoprogressive renal cell carcinoma (mRCC) treated with stereotactic radiosurgery (SRS), stratified by changing or continuing systemic treatment. PATIENTS AND METHODS: Ninety-five consecutive patients with clear cell mRCC who had undergone SRS to the central nervous system (CNS) or spine during systemic treatment were divided into 3 cohorts: those who continued the same systemic therapy (STAY), those who changed systemic treatment after SRS (SWITCH), and patients with progression outside the SRS sites, who also changed systemic treatment (PD-SYS)...
August 17, 2018: Clinical Genitourinary Cancer
Keiichi Ito, Shuji Mikami, Katsunori Tatsugami, Naoya Masumori, Nobuo Shinohara, Tsunenori Kondo, Shotaro Nakanishi, Yoji Nagashima, Masatoshi Eto, Tomomi Kamba, Naoto Kuroda, Yoshihiko Tomita, Hideyasu Matsuyama, Tetsuro Onishi, Tomoyasu Tsushima, Hayakazu Nakazawa, Mototsugu Oya, Seiichiro Ozono, Seiji Naito, Tomohiko Asano
BACKGROUND: Standard treatments have not been established in metastatic papillary renal-cell carcinoma (PRCC). We aimed to investigate treatment outcomes in patients with mPRCC. PATIENTS AND METHODS: This study included 51 patients who were diagnosed with PRCC at 14 institutions. Pathologic slides were reviewed by pathologists. The associations between clinical factors and overall survival (OS) were analyzed. RESULTS: Final pathologic diagnoses could be determined in 50 patients...
August 11, 2018: Clinical Genitourinary Cancer
Mirja Dombrowski, Matthias May, Philipp Julian Spachmann, Manju Ganesh Kumar, Hans-Martin Fritsche, Sabine Brookman-May, Odilo Maurer, Maximilian Burger, Christian Gilfrich
PURPOSE: Our objective was to investigate whether patients with urologic tumors were aware of smoking as a risk factor for the development and progression of several urologic cancers and the extent of the medical education they had received. Another aim was to investigate whether gender or age influenced patients' willingness to change their smoking habits. MATERIALS AND METHODS: Patients with histologically malignant urologic tumors were enrolled in our questionnaire-based study from September 2013 to December 2014 in 2 urology departments...
August 11, 2018: Clinical Genitourinary Cancer
Takayuki Nakayama, Kazutaka Saito, Jiro Kumagai, Yutaka Nakajima, Toshiki Kijima, Soichiro Yoshida, Kazunori Kihara, Yasuhisa Fujii
INTRODUCTION: C-reactive protein (CRP), a representative inflammatory marker, could serve as a biomarker in renal cell carcinoma because CRP is an important prognostic factor. However, its detailed mechanism remains unknown. This study showed that higher CRP levels correlated with the tumor immune microenvironment, which leads to a worse prognosis. These findings can help to clarify the underlying mechanisms between the presence of systemic inflammatory reaction and prognosis. The aim of this study is to investigate the association between tumor immune microenvironment and CRP in patients with renal cell carcinoma (RCC) to explore the underlying mechanisms between CRP level and prognosis...
August 11, 2018: Clinical Genitourinary Cancer
Maxine D Fisher, Rahul Shenolikar, Paul J Miller, Moon Fenton, Mark S Walker
INTRODUCTION: Current real-world data regarding treatment patterns in advanced bladder cancer in the community setting are limited. This study describes patient characteristics, treatment patterns, and effectiveness outcomes for stage IV bladder cancer in the community setting. METHODS: Medical records data of adults diagnosed with stage IV bladder cancer between January 1, 2008 and June 1, 2015 were retrospectively collected from a network of United States community oncology practices...
August 11, 2018: Clinical Genitourinary Cancer
Desiree Louise Draeger, Karl-Dietrich Sievert, Oliver W Hakenberg
BACKGROUND: In the field of uro-oncology, the assessment of quality of life (QoL) is considered an integral part of clinical research. Because of the rarity of penile cancer, there is currently no cancer-specific questionnaire module available to assess the tumor-specific loss of function and symptoms in terms of influencing QoL. The aim of the study was to apply a validated questionnaire (European Organization for Research and Treatment of Cancer [EORTC] QLQ-C30) in a population of patients diagnosed with penile cancer and to compare these results to reference data of the general population...
August 11, 2018: Clinical Genitourinary Cancer
Valérie Fonteyne, Elke Rammant, Piet Ost, Yolande Lievens, Bart De Troyer, Sylvie Rottey, Gert De Meerleer, Daan De Maeseneer, Dirk De Ridder, Karel Decaestecker
INTRODUCTION: There is a gap between optimal and actual use of radiotherapy (RT) in muscle-invasive bladder cancer (MIBC). We investigated the opinions of radiation-oncologists, urologists, and medical oncologists on use of RT in different cases. Barriers and facilitators for applying guidelines were examined. MATERIAL AND METHODS: A web-based survey was developed at Ghent University Hospital and conducted from November 18, 2016 to July 17, 2017. The place of primary, adjuvant, and palliative RT was evaluated...
August 11, 2018: Clinical Genitourinary Cancer
Gerald B Schulz, Tobias Grimm, Alexander Buchner, Friedrich Jokisch, Alexander Kretschmer, Jozefina Casuscelli, Brigitte Ziegelmüller, Christian G Stief, Alexander Karl
BACKGROUND: The purpose of this study was to investigate major complications and risk factors for adverse clinical outcome in surgical high-risk (American Society of Anesthesiologists [ASA] 3-4) patients undergoing radical cystectomy (RC) in a high-volume setting. PATIENTS AND METHODS: A total of 1206 patients underwent RC between 2004 and 2017 in our institution and were included. We assessed complications graded by the Clavien-Dindo-Classification system (CDC) in addition to the 90-day mortality rate and stratified results by the ASA classification...
August 1, 2018: Clinical Genitourinary Cancer
Michael E Hurwitz, Paul Markowski, Xiaopan Yao, Hari Deshpande, Jaymin Patel, Amir Mortazavi, Alessia Donadio, Mark N Stein, William Kevin Kelly, Daniel Peter Petrylak, Janice M Mehnert
BACKGROUND: Sorafenib, an oral tyrosine kinase inhibitor, may enhance the antitumor activity of platinum-based chemotherapy in transitional-cell carcinoma. This study investigated the safety and clinical outcome of adding sorafenib to gemcitabine and carboplatin for patients with advanced transitional-cell carcinoma. PATIENTS AND METHODS: Subjects with metastatic or unresectable chemotherapy-naive TCC with Eastern Cooperative Oncology Group performance status 0 or 1 received gemcitabine (1000 mg/m2 on days 1 and 8) and carboplatin (area under the curve of 5 on day 1) with sorafenib (400 mg 2 times a day on days 22-19 every 21 days) for 6 cycles...
July 29, 2018: Clinical Genitourinary Cancer
Carlo Cattrini, Alessandra Rubagotti, Pier Vitale Nuzzo, Linda Zinoli, Sandra Salvi, Simona Boccardo, Marta Perachino, Luigi Cerbone, Giacomo Vallome, Maria Maddalena Latocca, Elisa Zanardi, Francesco Boccardo
BACKGROUND: Overexpression of periostin (POSTN) is associated with prostate cancer (PCa) aggressiveness. We investigated the prognostic significance of POSTN expression in tumor biopsy samples of patients with PCa. METHODS: We scored POSTN expression by immunohistochemistry analysis on 215 PCa biopsy samples using an anti-POSTN-specific antibody. A total immunoreactive score (T-IRS) was calculated by adding the POSTN staining scores of stromal and epithelial tumor cells...
July 29, 2018: Clinical Genitourinary Cancer
Lucio Dell'Atti, Simone Scarcella, Stefano Manno, Massimo Polito, Andrea B Galosi
PURPOSE: We report an unclamped sutureless laparoscopic simple enucleation (LSE) technique for renal tumors with low nephrometry score and analyze complication rates as well as functional and oncologic outcomes. PATIENTS AND METHODS: We reviewed the data of 143 consecutive patients who underwent sutureless laparoscopic tumor enucleation with zero ischemia by a single experienced laparoscopic surgeon. The inclusion criteria for LSE with zero ischemia were tumor size ≤ 5 cm and RENAL nephrometry score of 4 to 6...
July 26, 2018: Clinical Genitourinary Cancer
Karim Fizazi, Matthew R Smith, Bertrand Tombal
Prostate cancer (PC) is the second most common cancer in men and is the fifth leading cause of cancer-related deaths among men. Androgen receptor (AR) signaling plays a key role in PC tumor growth and progression, with androgens stimulating PC proliferation and survival. Castration-resistant PC (CRPC) is characterized by increasing levels of prostate-specific antigen or radiographic progression despite androgen-deprivation therapy (ADT). In most patients, castration resistance results from aberrations in AR or the AR signaling pathway...
July 24, 2018: Clinical Genitourinary Cancer
Amanda Nizam, Edmond L Paquette, Brant G Wang, Jeanny B Aragon-Ching
No abstract text is available yet for this article.
July 23, 2018: Clinical Genitourinary Cancer
Congcong Wu, Wenjun Chen, Xuanzhang Huang, Ruifang Lin, Jian Wu, Xi Zhang
Patients receiving androgen deprivation therapy are associated with increasing loss of bone mineral density (BMD) and higher risk of skeletal-related events. We reviewed and analyzed the influence of diphosphonates on BMD change. A systemic literature research was conducted in PubMed and related bibliographies. The focus of data extraction was BMD percentage change of lumbar spine, total hip, and femoral neck after 12 months. Standardized mean difference (SMD) was pooled with the random-effects model, and metaregression and subgroup analysis were performed to explore heterogeneity...
July 21, 2018: Clinical Genitourinary Cancer
Darren M C Poon, Kenneth C W Wong, T W Chan, Kitty Law, Kuen Chan, Eric K C Lee, Conrad Lee, Michelle Chan
BACKGROUND: The present study retrospectively evaluated the efficacy and safety of enzalutamide in different lines of metastatic castration-resistant prostate cancer (mCRPC) treatment in a real-world setting. PATIENTS AND METHODS: The clinical records of patients with mCRPC treated with enzalutamide between August 2015 and October 2017 were retrieved from all 7 public oncology centers in Hong Kong and reviewed. The primary endpoint was progression-free survival (PFS) in first (1L), second (2L), and third or fourth lines (3L or 4L) of CRPC treatment...
July 21, 2018: Clinical Genitourinary Cancer
Rosario F Di Stefano, Consuelo Buttigliero, Emmanuele De Luca, Maria Lucia Reale, Chiara Pisano, Gianmarco Leone, Clizia Zichi, Federica Massa, Matteo Manfredi, Francesca Vignani, Enrico Bollito, Francesco Porpiglia, Massimo Di Maio, Marcello Tucci
No abstract text is available yet for this article.
July 21, 2018: Clinical Genitourinary Cancer
Thabo Lengana, Ismaheel O Lawal, Tebatso G Boshomane, Gbenga O Popoola, Kgomotso M G Mokoala, Evelyn Moshokoa, Alex Maes, Neo P Mokgoro, Christophe Van de Wiele, Mariza Vorster, Mike M Sathekge
PURPOSE: 68 Ga ligands targeting prostate-specific membrane antigen (PSMA) are rapidly emerging as a significant step forward in the management of prostate cancer. PSMA is a type II transmembrane protein with high expression in prostate carcinoma cells. We prospectively evaluated the use of 68 Ga-PSMA positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer and compared the results to those for technetium-99m (99m Tc)-10-metacyloyloxydecyl dihydrogen phosphate (MDP) bone scintigraphy (BS)...
July 21, 2018: Clinical Genitourinary Cancer
Joan Carles, Daniel Castellano, María-José Méndez-Vidal, Begoña Mellado, María-Isabel Saez, Aránzazu González Del Alba, José-Luis Perez-Gracia, José Jimenez, Cristina Suárez, Juan M Sepúlveda, Ray Manneh, Ignacio Porras, Cristina López, Rafael Morales-Barrera, José-Ángel Arranz
INTRODUCTION: Although increasing numbers of therapies with proven survival benefits have become available for metastatic castration-resistant prostate cancer (mCRPC), including radium-223, there is still a need for reliable biomarkers that provide information about clinically meaningful outcomes and treatment responses. MATERIALS AND METHODS: This study was a translational study that was conducted prospectively by the Spanish Oncology Genito-Urinary Group and included 45 patients with histologically confirmed mCRPC who were treated with radium-223...
July 21, 2018: Clinical Genitourinary Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"